Trial · NCT04234568
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Triapine and Recommended Phase 2 Dose (RP2D) | Escalation Phase | 150 | milligrams | ||
| Maximum Tolerated Dose (MTD) of Triapine and Recommended Phase 2 Dose (RP2D) | Expansion Phase | 150 | milligrams | ||
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 1 (100mg Triapine) | Grade 4 Neutropenia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 2 (150mg Triapine) | Grade 4 Neutropenia | 2 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 3 (200mg Triapine) | Grade 4 Neutropenia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 1 (100mg Triapine) | Grade 4 Neutropenia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 2 (150mg Triapine) | Grade 4 Neutropenia | 5 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 1 (100mg Triapine) | Grade 5 Cardiac Arrest | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 2 (150mg Triapine) | Grade 5 Cardiac Arrest | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 3 (200mg Triapine) | Grade 5 Cardiac Arrest | 1 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 1 (100mg Triapine) | Grade 5 Cardiac Arrest | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 2 (150mg Triapine) | Grade 5 Cardiac Arrest | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 1 (100mg Triapine) | Grade 3 Anemia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 2 (150mg Triapine) | Grade 3 Anemia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Escalation Phase Dose Level 3 (200mg Triapine) | Grade 3 Anemia | 0 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 1 (100mg Triapine) | Grade 3 Anemia | 1 | participants | |
| Dose Limiting Toxicity (DLT) | Expansion Phase Dose Level 2 (150mg Triapine) | Grade 3 Anemia | 0 | participants | |
| Overall Response Rate (ORR) | Escalation Phase Dose Level 1 (100mg Triapine) | 33.3 | percentage of participants | ||
| Overall Response Rate (ORR) | Escalation Phase Dose Level 2 (150mg Triapine) | 18.2 | percentage of participants | ||
| Overall Response Rate (ORR) | Expansion Phase Dose Level 1 (100mg Triapine) | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04234568/results